These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 22761788

  • 1. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
    Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM.
    PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
    [Abstract] [Full Text] [Related]

  • 2. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
    Hotta R, Ohira M, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, Vianna R, Ohdan H, Waldmann H, Tzakis AG, Nishida S.
    PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
    [Abstract] [Full Text] [Related]

  • 3. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.
    Dons EM, Raimondi G, Zhang H, Zahorchak AF, Bhama JK, Lu L, Ezzelarab M, Ijzermans JN, Cooper DK, Thomson AW.
    Am J Transplant; 2013 Aug; 13(8):2169-78. PubMed ID: 23635093
    [Abstract] [Full Text] [Related]

  • 4. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
    Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A.
    PLoS One; 2014 Aug; 9(7):e103254. PubMed ID: 25050704
    [Abstract] [Full Text] [Related]

  • 5. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
    Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM.
    Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
    [Abstract] [Full Text] [Related]

  • 6. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.
    Ambrose LR, Morel AS, Warrens AN.
    Blood; 2009 Oct 01; 114(14):3052-5. PubMed ID: 19638623
    [Abstract] [Full Text] [Related]

  • 7. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
    Pulaski HL, Spahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, Coukos G, Conejo-Garcia JR, Buckanovich RJ.
    J Transl Med; 2009 Jun 19; 7():49. PubMed ID: 19545375
    [Abstract] [Full Text] [Related]

  • 8. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW.
    Blood; 2003 Feb 15; 101(4):1422-9. PubMed ID: 12393688
    [Abstract] [Full Text] [Related]

  • 9. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S, Pryce G, Giovannoni G, Baker D.
    Immunology; 2017 Apr 15; 150(4):444-455. PubMed ID: 27925187
    [Abstract] [Full Text] [Related]

  • 10. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.
    Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S.
    Blood; 2002 Sep 01; 100(5):1715-20. PubMed ID: 12176892
    [Abstract] [Full Text] [Related]

  • 11. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
    Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M.
    Br J Haematol; 2009 Apr 01; 145(2):173-9. PubMed ID: 19236377
    [Abstract] [Full Text] [Related]

  • 12. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
    Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH.
    Blood; 2010 Dec 23; 116(26):5930-40. PubMed ID: 20844239
    [Abstract] [Full Text] [Related]

  • 13. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
    Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC.
    Leukemia; 2006 Feb 23; 20(2):272-9. PubMed ID: 16341049
    [Abstract] [Full Text] [Related]

  • 14. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
    Turner MJ, Lamorte MJ, Chretien N, Havari E, Roberts BL, Kaplan JM, Siders WM.
    J Neuroimmunol; 2013 Aug 15; 261(1-2):29-36. PubMed ID: 23759318
    [Abstract] [Full Text] [Related]

  • 15. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
    Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, Dunlop A, Catovksy D.
    Leuk Lymphoma; 2005 May 15; 46(5):723-7. PubMed ID: 16019510
    [Abstract] [Full Text] [Related]

  • 16. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS.
    Leuk Lymphoma; 2007 Dec 15; 48(12):2424-36. PubMed ID: 18067019
    [Abstract] [Full Text] [Related]

  • 17. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
    Holgate RG, Weldon R, Jones TD, Baker MP.
    PLoS One; 2015 Dec 15; 10(9):e0138123. PubMed ID: 26372145
    [Abstract] [Full Text] [Related]

  • 18. Expression of CD52 in peripheral T-cell lymphoma.
    Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA.
    Haematologica; 2007 Apr 15; 92(4):566-7. PubMed ID: 17488672
    [Abstract] [Full Text] [Related]

  • 19. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
    Siders WM, Shields J, Garron C, Hu Y, Boutin P, Shankara S, Weber W, Roberts B, Kaplan JM.
    Leuk Lymphoma; 2010 Jul 15; 51(7):1293-304. PubMed ID: 20377308
    [Abstract] [Full Text] [Related]

  • 20. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, Herndlhofer S, Streubel B, Rabitsch W, Sperr WR, Mayerhofer M, Rülicke T, Valent P.
    Clin Cancer Res; 2014 Jul 01; 20(13):3589-602. PubMed ID: 24799522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.